Clinical Lipidology: A Companion to Braunwald's Heart Disease E-Book, 2nd Edition
- Get authoritative guidance from some of the foremost experts in the field.
- Easily access key content with help from treatment algorithms.
Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style.
Key Features
- Get authoritative guidance from some of the foremost experts in the field.
- Easily access key content with help from treatment algorithms.
| ISBN | 9780323313261 |
|---|---|
| Author Information | By Christie M. Ballantyne, MD, FACP, FACC, Christie M. Ballantyne, MD, FACP, FACC Chief, Section of Cardiology Chief, Section of Cardiovascular Research Professor of Cardiovascular Medicine Baylor College of Medicine |
| Table of Content | Section 1 Basic Mechanisms 1. Human Plasma Lipoprotien Metabolism 2. Regulation and Clearance of Apolipoprotein B-Containing Lipoproteins 3. Absorption and Excretion of Intestinal Cholesterol and Other Sterols 4. High-Density Lipoprotein Metabolism 5. Lipoproteins: Mechanisms for Atherogenesis and Progression of Atherothrombotic Disease 6. Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism 7. Lipoprotein Oxidation: Mechanisms and Biotheranostic Applications Section 2 Risk Assessment 8. Cholesterol: Concentration, Ratio, and Particle Number 9. High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment 10. Lipoprotein(a) 11. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia 12. Use of High Sensitivity C-Reactive Protein for Risk Assessment 13. Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease 14. Emerging Assays 15. Imaging Atherosclerosis for Risk Stratification by Cardiac Computed Tomography or Carotid Ultrasound Section 3 Therapy 16. Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol 17. Treatment Guidelines Overview 18. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 19. Exercise and Lipids 20. Weight Loss 21. Statins 22. Bile Acid Sequestrants 23. Cholesterol Absorption Inhibitors 24. Niacin (Nicotinic Acid) 25. Fibrates 26. Omega-3 Fatty Acids 27. Combination Therapy for Dyslipidemia 28. Nutriceuticals and Functional Foods for Cholesterol Reduction 29. Evolving Targets of Therapy: Cholesteryl Ester Transfer Protein Inhibition 30. Evolving Targets of Therapy: Proprotein Convertase Subtilisin/Kexin 9 Inhibition 31. Evolving Targets of Therapy: Inflammation as a Method to Predict and Prevent Cardiovascular Events 32. Invasive Imaging Modalities and Atherosclerosis: Intravascular Ultrasound 33. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound 34. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Magnetic Resonance Imaging and Positron Emission Tomography Imaging 35. Special Patient Populations: Diabetes and Metabolic Syndrome 36. Special Patient Populations: Women and Elderly 37. Special Patient Populations: Children and Adolescents 38. Special Patient Populations: Familial Hypercholesterolemia and other Severe Hypercholesterolemias 39. Special Patient Populations: Acute Coronary Syndromes 40. Special Patient Populations: Transplant Recipients 41. Special Patient Populations: Chronic Kidney Disease 42. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups 43. Special Patient Populations: Human Immunodeficiency Patients 44. Therapeutic Targeting of High-Density Lipoprotein Metabolism |
| Publication Date | 14-11-2014 |
| Pages | 608 |
| deltacomm1code | Electronic Book |
